ORIGINAL

 

Epidemiological aspects of critically ill Covid-19 patients: a non-concurrent cohort study*

 

Roberta Maria de Jesus1, Luana Vieira Toledo2, Juliana Soares Jardim1, José Ferreira Pires Júnior1, Luciana Valverde Vieira Delfim1, Juliana de Souza Lima Coutinho2, Silvânia Medina de Souza2, Flávia Falci Ercole1

 

1 Federal University of Minas Gerais, School of Nursing, MG, Brazil

2 Federal University of Viçosa, Department of Medicine and Nursing, MG, Brazil

 

ABSTRACT

Objective: to analyze the epidemiological aspects and factors associated with the survival of critically ill patients diagnosed with Covid-19. Method: this is a non-concurrent cohort study with information from 205 critically ill Covid-19 patients. Results: the incidence and lethality of Covid-19 were, respectively, 60.3% and 46.8%. The mean survival time of patients was 21.8 days, and the factors associated with lower survival were high score on the Simplified Acute Physiology Score, shorter time on mechanical ventilation, altered level of consciousness, use of a central venous catheter, presence of coagulopathies and need for cardiopulmonary resuscitation. Patients on oxygen therapy by nasal cannula had better survival. Conclusion: there was a high incidence and lethality of the disease among critically ill patients. The lowest survival rate was related to indicators of greater severity of the clinical picture. The results support nurses in planning patient care to minimize the risk of death.

 

Descriptors: COVID-19; Intensive Care Units; Nursing.

 

INTRODUCTION

In December 2019, in the city of Wuhan, the capital of Hubei province in China, an outbreak of people with pneumonia of unknown cause occurred. Chinese scientists isolated a new coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) from samples of these patients due to its similarity to the virus that causes Severe Acute Respiratory Syndrome (SARS). The disease caused by this new coronavirus has been designated as Coronavirus Disease 2019 (Covid-19), considered a pandemic by the World Health Organization (WHO) in March 2020(1-2).

The transmission of the SARS-CoV-2 virus occurs by respiratory droplets during the regular speech, coughing, sneezing, and through aerosols from symptomatic people. Clinical manifestations may appear between one and fourteenth days after exposure(3).

The number of cases of Covid-19 has increased exponentially in several countries worldwide. According to WHO data released until July 9, 2021, there were 185,291,530 confirmed cases and 4,010,834 deaths(4). According to data released by the Brazilian Ministry of Health (MS), on July 10, 2021, Brazil reported 19,069,003 confirmed cases and 532,893 deaths(5).

Although most people with Covid-19 develop the disease with mild or moderate symptoms, approximately 15% manifest the severe form, which requires hospitalization with supplemental oxygen support. Among patients with the severe form of the disease, 5% have complications such as respiratory failure, Acute Respiratory Distress Syndrome (ARDS), sepsis, septic shock, thromboembolism, acute kidney failure, and heart damage. Advanced age, smoking history, and underlying non-communicable diseases, such as arterial hypertension, chronic lung disease, obesity, and cancer, have been reported as risk factors for the worsening of the disease and worse prognosis(3).

In the world and Brazil, with the progression of the pandemic, a greater demand for Intensive Care Unit (ICU) beds has been observed for patients with severe forms of the disease, which caused an overload on the health system. In Brazil, the existing regional disparities, especially concerning access to health services and the concentration of ICU beds in the Southeast Region, aggravated the impact of Covid-19. Between February and August 2020, 205,493 ICU admissions of Covid-19 patients were registered in Brazil, of which 59% died. When evaluating mortality by region, it is clear that these values in the North and Northeast ​​were even higher, representing 79% and 66%(6).

In this context, a crisis began with a high number of critically ill patients waiting for healthcare. Despite efforts to acquire equipment and create new ICU beds, the number of specialized intensive care professionals was insufficient to meet the demand of critically ill patients. Thus, health institutions and managers were forced to hire professionals with less experience to assist in the treatment of these patients without prior training(7-8).

Given the high transmission of SARS-CoV-2 in the population, the uncertainties arising from the development of the disease and the consequences for patients, as well as the great demand for ICU beds and the difficulty in adapting hospitals to face the pandemic, the following question emerged: what are the epidemiological aspects and factors associated with the survival of critical Covid-19 patients admitted to a philanthropic hospital in Belo Horizonte, Minas Gerais (MG)?

Thus, the objective of this study was to analyze the epidemiological aspects and factors associated with the survival of critically ill patients diagnosed with Covid-19.

 

METHOD

A non-concurrent cohort study was carried out based on information available in the medical records of critically ill Covid-19 patients admitted to the ICU of a philanthropic hospital in Belo Horizonte, MG, Brazil, from May to December 2020. This ICU has 30 beds, structured for the care of patients with suspected or confirmed Covid-19 due to the demand caused by the pandemic.

The study population consisted of 340 critically ill patients admitted to the ICU-Covid during the study period. Patients aged 18 years or older, confirmed with COVID-19 through clinical and laboratory diagnoses, were included. Patients with an inconclusive or negative Covid-19 laboratory test result were excluded. The final sample consisted of 205 patients who had their medical records evaluated. Data from medical records were collected using an instrument elaborated by the researchers, containing characterization data and clinical and epidemiological information. Data collection was carried out from January to March 2021.

The variables collected were: hospitalization outcome (discharge/death), age, gender, origin, presence of comorbidities, date of admission to the ICU, date of hospitalization outcome, length of stay in the ICU, time until the occurrence of the hospitalization outcome, Simplified Acute Physiology Score (SAPS III), clinical manifestations presented by the patient, invasive devices used, interventions performed (hemodialysis, blood transfusion, prone positioning, cardiopulmonary resuscitation, and virtual visit), and pharmacological treatments administered.

Data were double-entered into Microsoft Office Excel software, version 2016. Then, they were exported and analyzed using the Statistical Package for Social Sciences, version 23.0.

Descriptive and inferential analyzes were performed. The Kolmogorov-Smirnov test evaluated the normality of the variables. For descriptive analysis, absolute and relative frequency distributions, measures of central tendency, and variability measures were used, according to the normality test results.

The incidence and lethality rates of Covid-19 among critically ill patients were calculated. The characteristics of critically ill patients who survived or not were compared to identify the differences between the profiles of these patients. Categorical variables were compared using Pearson's chi-square test. We used the Student's T-test for independent samples (parametric variables) and the Mann Whitney test (variables with non-parametric distribution) for numerical variables. The values ​​of p<0.05 were considered statistically significant.

Survival analysis was performed to assess the factors associated with the survival of critically ill Covid-19 patients, considering as a dependent variable the observation time, in days, until the occurrence of the outcome. The outcomes were death or discharge, indicating the end of the observation period (censorship). The Kaplan-Meier estimator was used to estimate the probability of survival of critically ill Covid-19 patients.

The Log-rank, Breslow, and Tarone-Wire tests were applied to determine the statistical significance of the survival curves. The variables that presented p<0.05 in all three tests were adopted as significant variables(9). Variables with statistical significance were included in the multivariate analysis using Cox regression. The Hazard Ratio (HR) and the respective 95% Confidence Intervals (95%CI) were estimated to identify the factors associated with the death of critically ill Covid-19 patients.

The study complied with the Guidelines established in Resolution 466/12 of the National Health Council. Data collection began after approval by the Research Ethics Committee of the proposing institution, under opinion No. 4,349,612, and by the Research Ethics Committee of the co-participating institution, under opinion No. 4,465,956.

 

RESULTS

During the period evaluated, 340 critically ill patients were hospitalized. The incidence of critically ill patients hospitalized due to Covid-19 was 60.3% (205 patients), with a case fatality rate of 46.8%. From the comparison of patients who died or not, it was found that among those who died, there was a greater proportion of elderly patients (p=0.001), males (p=0.036), and patients who had comorbidities prior to hospitalization (p=0.020), as shown in Table 1.

 

Table 1 – Characteristics of critically ill patients diagnosed with Covid-19 (n=205). Belo Horizonte, MG, Brazil, 2020

Variables

Survivors

(n=109)

Non-Survivors (n=96)

p-value

Average age (years) (Q1-Q3)

63.0(53.0-71.0)

68.0 (60.2-77.0)

0.001

<60 years

42 (38.5)

21 (21.9)

0.010

≥ 60 years

67 (61.5)

75 (78.1)

 

Gender n (%)

 

 

0.036

Female

46 (42.2)

27 (28.1)

 

Male

63 (57.8)

69 (71.9)

 

Origin n(%)

 

 

0.551

Wards

43 (39.4)

38 (39.6)

 

Emergency service

28 (25.7)

27 (28.1)

 

Outpatient units

17 (15.6)

15 (15.6)

 

Intensive Care Units

-

2 (2.1)

 

Other

21 (19.3)

14 (14.6)

 

Comorbidities n (%)

 

 

0.020

No

13 (11.9)

3 (3.1)

 

Yes

96 (88.1)

93 (96.9)

 

Type of comorbidities n (%)

 

 

 

Systemic Arterial Hypertension

68 (62.4)

71 (74.0)

0.077

Diabetes mellitus

36 (33.0)

30 (31.3)

0.881

Neoplasms

28 (25.7)

27 (28.1)

0.694

Obesity

28 (25.7)

15 (15.6)

0.077

COPD

9 (8.3)

20 (20.8)

0.010

Dyslipidemia

14 (12.8)

15 (15.6)

0.569

Chronic Kidney Disease

9 (8.3)

16 (16.7)

0.066

Acute myocardial infarction

11 (10.1)

11 (11.5)

0.752

Psychiatric Disorder

10 (9.2)

11 (11.5)

0.590

Heart disease

12 (11.0)

9 (9.4)

0.700

Stroke

4 (3.7)

6 (6.3)

0.520

Pneumonia

4 (3.7)

5 (5.2)

0.592

Asthma

3 (2.8)

3 (3.1)

1,000

Dementia

3 (2.8)

2 (2.1)

1,000

Source: Elaborated by the authors, 2021.

 

Table 2 compares the clinical and epidemiological characteristics of critically ill Covid-19 patients who survived or not. Notably, patients who died had higher SAPS III scores and higher estimated mortality (p<0.001).

 

Table 2 – Clinical and epidemiological characteristics of critically ill patients diagnosed with Covid-19 (n=205). Belo Horizonte, MG, Brazil, 2020

Variables

Survivors

(n=109)

Non-Survivors (n=96)

p-value

Length of ICU stay (days) med (Q1-Q3)

8.0 (3.0-13.5)

7.0 (3.2-18.0)

0.129

SAPS III score m(±sd)

47.8 (±12.8)

57.4 (±12.9)

<0.001

Estimated SAPS III Mortality m(±sd)

20.0% (±18.5)

32.7% (±22.3)

<0.001

Clinical Manifestations n(%)

 

 

 

Ageusia

8 (7.3)

3 (3.1)

0.224

Agitation

1 (0.9)

5 (5.2)

0.067

Alteration of the level of consciousness

43 (39.4)

87 (90.6)

<0.001

Anosmia

11 (10.1)

5 (5.2)

0.193

Anxiety

12 (11.1)

9 (9.4)

0.684

Septic shock

24 (22.0)

51 (53.1)

<0.001

Coagulopathies

4 (3.7)

12 (12.5)

0.019

Mental confusion

15 (13.8)

20 (20.8)

0.179

Convulsion

1 (0.9)

5 (5.2)

0.100

Acute pain

49 (45.0)

27 (28.1)

0.013

Skin rashes

24 (22.0)

25(26.0)

0.500

Fatigue

21 (19.3)

16 (16.7)

0.629

Fever

65 (59.6)

65 (67.7)

0.231

Weakness

13 (11.9)

17 (17.7)

0.243

Bleeding

3 (2.8)

9 (9.4)

0.044

Hyperglycemia

59 (54.1)

63 (65.9)

0.094

Arterial hypertension

63 (57.8)

40 (41.7)

0.021

Arterial hypotension

245 (22.0)

57 (59.4)

<0.001

Hypoxemia

42 (38.5)

59 (61.5)

0.001

Liver injury

31 (28.4)

34 (35.4)

0.284

Lung injury

61 (56.0)

68 (70.8)

0.028

Acute kidney injury

44 (40.4)

72 (75.0)

<0.001

Myalgia

21 (19.3)

15 (15.6)

0.494

Nausea

4 (3.7)

7 (7.3)

0.354

SARS

43 (39.4)

57 (59.3)

0.003

Tachycardia

20 (18.3)

30 (30.1)

0.032

Tachypnea

97 (89.0)

84 (87.5)

0.740

Dizziness

2 (1.8)

1 (1.0)

1,000

Cough

87 (79.8)

71 (74.0)

0.319

Vomiting

7 (6.4)

9 (9.4)

0.432

Invasive devices n(%)

 

 

 

Nasoenteric tube (NET)

47 (43.1)

69 (71.9)

<0.001

Central venous catheter (CVC)

53 (48.6)

91 (94.8)

<0.001

Indwelling Urinary Catheter (IDC)

69 (63.3)

88 (91.7)

<0.001

Peripheral venous catheter (PVC)

103 (94.5)

91 (94.8)

0.925

Drains

-

6 (6.3)

0.010

Invasive blood pressure (IBP)

103 (94.5)

96 (100.0)

0.020

Oxygen therapy through nasal cannula (NC)

97 (89.0)

31 (32.3)

<0.001

Oxygen therapy through macro mask

12 (11.0)

7 (7.3)

0.360

Oxygen therapy through reservoir mask

68 (62.4)

48 (50.0)

0.074

Invasive mechanical ventilation (IMV)

48 (44.0)

94 (97.8)

<0.001

Non-invasive ventilation

17 (15.6)

19 (19.8)

0.431

IMV days m (±dp)

4.0 (± 6.4)

10.5 (± 10.7)

<0.001

Interventions carried out n(%)

 

 

 

Hemodialysis

14 (12.8)

61 (63.5)

<0.001

Blood transfusion

15 (13.8)

35 (36.5)

<0.001

Prone positioning

52 (47.7)

47 (49.0)

0.858

Cardiopulmonary resuscitation (CPR)

5 (4.6)

44 (45.8)

<0.001

Virtual visit

91 (83.5)

75 (78.1)

0.329

Source: Elaborated by the authors, 2021.

 

Regarding the pharmacological treatments used by patients during ICU stay, it was found that among patients who died, there was a higher proportion of patients who used sedatives (91.7%) and vasoactive drugs (92.7%) when compared to those who survived (p<0.05), as shown in Table 3.

 

Table 3 – Pharmacological treatments used by critically ill patients diagnosed with Covid-19 (n=205). Belo Horizonte, MG, Brazil, 2020

Variables

Survivors

(n=109)

Non-Survivors (n=96)

p-value

Pharmacological classes n(%)

 

 

 

Beta-adrenergic agonist

29 (26.6)

28 (29.2)

0.683

Analgesics

58 (53.2)

69 (71.9)

0.006

Antibiotics

106 (97.2)

94 (97.9)

0.757

Anxiolytics

17 9 (15.6)

19 (19.8)

0.431

Antacids

93 (85.3)

87 (90.6)

0.247

Antidiabetic drugs

59 (54.1)

64 (66.7)

0.067

Anticoagulants

102 (93.6)

85 (88.5)

0.204

Antifungals

12 (11.0)

19 (19.8)

0.080

Antihypertensives

46 (42.2)

24 (25.0)

0.010

Anti-inflammatories

2 (1.8)

6 (6.3)

0.150

Antiplatelet

4 (3.7)

6 (6.3)

0.520

Antivirals

28 (25.7)

23 (24.0)

0.775

Antipyretics

41 (37.6)

57 (59.4)

0.002

Beta blockers

8 (7.3)

10 (10.4)

0.437

Neuromuscular blockers

22 (20.2)

49 (51.0)

<0.001

Corticosteroids

83 (76.1)

77 (80.2)

0.483

Diuretics

33 (30.3)

40 (41.7)

0.089

Immunosuppressants

1 (0.9)

6 (6.3)

0.036

Sedatives

50 (45.9)

88 (91.7)

<0.001

Vasoactive drugs

51 (46.8)

89 (92.7)

<0.001

Source: Elaborated by the authors, 2021.

 

The mean patient survival time was estimated at 21.8 days. In the univariate analysis, there was a difference in the mortality of critically ill Covid-19 patients concerning the SAPS III score, estimated SAPS III mortality, altered level of consciousness, coagulopathy, acute pain, hypertension, hypotension, use of CVC, oxygen therapy by nasal cannula, invasive mechanical ventilation (IVM), IMV duration, CPR, and use of antihypertensive, sedative and vasoactive drugs (Log rank p<0.05; Breslow p<0.05; and Tarone-Ware p<0.05), as shown in Table 4.

 

Table 4 –Log rank, Breslow, and Tarone-Ware test results for the factors associated with survival of critically ill patients diagnosed with Covid-19 (n=205). Belo Horizonte, MG, Brazil, 2020

Variable

Log rank

(p-value)

Breslow

(p-value)

Tarone-Ware

(p-value)

SAPS III score

<0.001

<0.001

<0.001

Estimated SAPS III mortality

<0.001

<0.001

<0.001

Altered level of consciousness

0.008

0.002

0.004

Coagulopathies

0.004

0.004

0.003

Acute pain

0.000

0.002

0.000

Hypertension

0.000

0.000

0.000

Hypotension

0.015

0.009

0.009

Central venous catheter

0.011

0.006

0.007

Oxygen therapy through nasal cannula

<0.001

<0.001

<0.001

IMV

0.001

0.001

0.001

IMV duration (days)

<0.001

<0.001

<0.001

Cardiopulmonary resuscitation

<0.001

<0.001

<0.001

Antihypertensive drugs

<0.001

<0.001

<0.001

Sedatives

0.048

0.019

0.023

Vasoactive drugs

0.017

0.005

0.007

Source: Elaborated by the authors, 2021.

 

In the multivariate analysis, based on Cox regression, the following factors were found to be associated with lower survival of critically ill patients: higher SAPS III score (HR: 1.021; 95%CI: 1.004-1.039), presence of altered level of consciousness (HR: 2.260; 95%CI: 1.078-4.735), shorter IMV duration (HR: 0.854; 95%CI: 0.819-0.889), use of CVC (HR: 3.166; 95%CI: 1.167-8.592), presence of coagulopathies (HR: 2.065; 95%CI: 1.097-3.886), and need for cardiopulmonary resuscitation (HR: 2.347; 95%CI: 1.529-3.602). In addition, it was found that patients who received oxygen therapy through nasal cannula had greater survival than those who did not use this device during ICU stay (HR: 0.176; 95%CI: 0.108-0.285), as shown in Table 5.

 

Table 5 – Results of the final Cox multivariate regression model for factors associated with lower survival of critically ill patients diagnosed with Covid-19 (n=205). Belo Horizonte, MG, Brazil, 2020

Variables

HR

95%CI

p-value

SAPS III score

1.021

1.004-1.039

0.017

Invasive mechanical ventilation duration

0.854

0.819-0.889

<0.001

Altered level of consciousness

2,260

1,078-4,735

0.031

Use of central venous catheter

3,166

1,167-8,592

0.024

Coagulopathies

2,065

1,097-3,886

0.025

Cardiopulmonary resuscitation

2,347

1,529-3,602

<0.001

Oxygen therapy by nasal cannula

0.176

0.108-0.285

<0.001

Source: Elaborated by the authors, 2021.

 

DISCUSSION

The pandemic imposed by the new coronavirus caused an increase in the number of patients admitted to the ICU with a diagnosis of Covid-19 and an increase in mortality. In Brazil, until December 2020, 59.0% of ICU admissions and 30.7% of deaths were due to Covid-19(7). Among the patients evaluated in this study, there was a case fatality rate of 46.8%, similar to the result of a cohort with 3,988 Italian patients, whose case fatality rate was 48.7%(10). In another study with 103 patients admitted to an ICU in New Jersey, the case fatality rate was even higher, reaching 61.1%(11). Thus, it is understood that lethality can be influenced by different factors, which include aspects related to the management and organization of the services and characteristics of the patients themselves, such as advanced age, male gender, and comorbidities including arterial hypertension, diabetes mellitus, and obesity(1,6-7,10-11).

This study found that a higher SAPS III score was associated with lower patient survival, demonstrating a relationship between the mortality estimated by this score and the actual mortality of patients. Different researchers have also described that Covid-19 patients admitted to the ICU with a higher SAPS III score evolved negatively and died(12-13).

It is important to highlight that many patients present a worsening clinical picture while waiting for ICU beds in Emergency Care Units in Brazil (UPAs in Portuguese), Emergency Rooms (ERs), or general wards. In these units, patients receive initial care, guided by clinical protocols, to control their clinical condition and reduce lethality while waiting for specialized care(3). However, this reorganization of care and services appears to configure major challenges imposed by the pandemic. According to data from the Minas Gerais State Health Department, on May 27, 2021, 253 patients were waiting for admission to ICU beds and another 410 to hospital beds. A study carried out in Brazil evaluated 522,167 medical records of patients with positive Covid-19, hospitalized in a public and private network, and it was described that admission to the ICU was one of the predictive factors for mortality since, on average, patients took six days to be admitted(7).

It is emphasized that critical patients generally have significant complications from Covid-19, especially pulmonary involvement. A national study showed that 47.8% of Covid-19 patients admitted to the ICU were from ERs, and 60.3% arrived intubated on IMV(12). In this study, shorter survival was associated with shorter IMV time, which may be related to late admission to the ICU, so that patients had greater disease severity and, consequently, died in the first days of ventilatory support. A study in São Paulo identified that the high severity of the disease at admission and the higher mortality of patients could be explained by the delay in ICU admission, reflecting the difficulties in accessing healthcare(13).

It is noteworthy that, in this study, the altered level of consciousness in critically ill patients was also a predictor of mortality. Similar results were found in multicentric studies carried out in several ICUs worldwide. These described that most patients admitted with ARDS due to Covid-19 were intubated in the first 24 hours, increasing the use of sedatives and neuromuscular blockers, resulting in more unconscious patients. These studies identified that patients with a long period of sedation and immobilization who were far from their families had a worse outcome(14). It is emphasized that sedation is included as a measure for treating Covid-19 patients, whose management must be individualized and adjustable over time to allow the patient to tolerate IMV, maintain an adequate oxygenation level, and reduce accidental extubation rates(15).

Another variable associated with lower survival found in this study was the use of CVC. A study with 1,000 intensive care physicians and anesthesiologists in France, Switzerland, Belgium, Portugal, and Brazil described that 98% of critically ill Covid-19 patients used CVC for drug administration and 79% for venous oxygen saturation measurement(16). Thus, it is noteworthy that Covid-19 patients admitted to the ICU can develop hemodynamic instability, and the use of the CVC is needed for drug administration and hemodynamic monitoring. Despite the importance of using the CVC for the treatment of patients, the risks related to this device cannot be ignored, especially the risk of infection, which can contribute to the worsening of the patient's general condition(17).

In this research, it was found that the presence of coagulopathies was also associated with lower patient survival. A meta-analysis of 35 studies suggests that the worsening of coagulation parameters may indicate progressive Covid-19 severity and a worse prognosis(18). In this context, the importance of antithrombotic therapy in the daily management of Covid-19, which had already been implemented in this study's scenario, is reinforced.

The clinical severity caused by the coronavirus can also lead patients to develop myocardial injury and cardiorespiratory arrest due to severe respiratory failure, hemodynamic instability, arrhythmias, septic shock, and hydro electrolytic disorders. The present study found a strong association between cardiorespiratory arrest and increased mortality, which is considered an indicator of worsening. In a study in Rio de Janeiro, cardiac involvement was also associated with a worse prognosis among critically ill Covid-19 patients(19).

It is important to emphasize that patients who received oxygen therapy by nasal cannula for some period during their ICU stay had greater survival than those who did not use this device. This finding can be explained by the fact that oxygen therapy through the nasal cannula is recommended at the initial stage of the treatment for patients with minor pulmonary involvement, as this device offers an oxygen supply of up to 5L/min without the need for humidification(3). Thus, patients who used this device at some point during their stay in the ICU were less severely compromised.

A study carried out in the ICU with Covid-19 patients showed satisfactory results with the use of the High Flow Nasal Catheter (HFNC) and a Non-Invasive Ventilation (NIV) mask. These devices reduced the number of patients undergoing IMV, reducing hospitalization time, infection, and mortality. The WHO recommends these devices provided professionals use Personal Protective Equipment (PPE) correctly(8).

Due to the tropism of the coronavirus spike (S) protein for type II alveolar epithelial cells, this viral infection can provoke an unregulated inflammatory response, causing tissue damage to lung cells, which culminates in pulmonary microvascular thrombosis, hindering gas exchange and predisposing to acute respiratory insufficiency(20). Therefore, early and individualized care is important, guided by evidence-based clinical protocols(3).

It is important to note that the ICU in this study faced several challenges imposed by the pandemic, such as the need to add hospital beds in a few days, and the acquisition of new medical equipment that is not frequently available in the clinical wards, and the immediate hiring of professionals. In addition, there was a shortage of medicines in Minas Gerais, Brazil, requiring professionals to evaluate new protocols for the dilution and administration of the most commonly used drugs. However, efforts by managers and professionals were directed toward training new professionals and updating clinical protocols to ensure quality care for patients with suspected or confirmed Covid-19.

This study has as a limitation the fact that it was carried out in a single ICU, which limits the generalization of the results due to the disparities in each region of the country. There is also the fact that documental analysis of the data available in medical records was used and not at the bedside. However, it is noteworthy that the sample of this study was larger than that found in other studies that analyzed data from only one ICU.

 

CONCLUSION

During the pandemic imposed by the new coronavirus, a high incidence of Covid-19 was observed among critically ill patients, with a predominance of elderly male patients who had some comorbidity. Although most patients were discharged from the ICU, there was a high mortality rate from Covid-19 among critically ill patients, demonstrating the high severity of this public health problem. The lowest patient survival was associated with patients with greater clinical severity, identified by the higher SAPS III score, shorter IMV time, presence of altered level of consciousness, use of CVC, presence of coagulopathies, and need for cardiopulmonary resuscitation. On the other hand, patients who used oxygen therapy by nasal cannula during hospitalization had greater survival.

It is believed that the findings of this study can help researchers, health professionals, and managers to know the epidemiological aspects and factors associated with the survival of critically ill Covid-19 patients and, thus, be able to outline work methodologies that contribute to minimizing the worsening of this disease, which remains a challenge.

It should be noted that the crisis triggered by the coronavirus disease should provide opportunities for the implementation of systemic approaches, according to the best available evidence.

 

CONFLICT OF INTEREST

The authors have declared that there is no conflict of interest.

 

 

* The manuscript is extracted from a dissertation “Epidemiological aspects of critically ill patients with Covid-19: a non-concurrent cohort study”, Federal University of Minas Gerais, School of Nursing, MG, Brazil.

 

REFERENCES

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. http://dx.doi.org/10.1016/S0140-6736(20)30566-3. Pmid:32171076.

 

2. World Health Organization. Coronavirus (COVID-19) outbreak [Internet]. 2020 [cited 2020 May 31]. Available from: https://www.who.int/westernpacific/emergencies/covid-19

 

3. Ministério da Saúde (BR), Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde (SCTIE). Diretrizes para diagnóstico e tratamento da Covid-19. [Internet]. Brasília, DF: Ministério da Saúde; 2020. [cited 2020 Apr 27]. Available from: https://pncq.org.br/uploads/2020-1/Diretriz-Covid19-v4-07-05.20h05m.pdf

 

4. World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2021 [cited 2021 July 9]. Available from: https://covid19.who.int/

 

5. Ministério da Saúde (BR). Painel Coronavírus [Internet]. Brasília, DF: Ministério da Saúde; 2021 [cited 2021 July 10]. Available from: https://covid.saude.gov.br/

 

6. Ranzani OT, Bastos LS, Gelli JG, Marchesi JF, Baião F, Hamacher S, et al. Characterisation of the first 250.000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Lancet Respir Med. 2021;9(4):407-18. PMid:33460571.

 

7. Castro MC, Gurzenda S, Macário EM, França GV. Characteristics, outcomes and risk factors for mortality of 522 167 patients hospitalised with COVID-19 in Brazil: a retrospective cohort study. BMJ Open. 2021;11(5):e049089. http://dx.doi.org/10.1136/bmjopen-2021-049089. PMid:33947740.

 

8. Holanda MA, Pinheiro BV. COVID-19 pandemic and mechanical ventilation: facing the present, designing the future. J Bras Pneumol. 2020;46(4):e20200282. http://dx.doi.org/10.36416/1806-3756/e20200282. PMid:32696835.

 

9. Miot HA. Survival analysis in clinical and experimental studies. J Vasc Bras. 2017;16(4):267-9. http://dx.doi.org/10.1590/1677-5449.001604. PMid:29930659.

 

10. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020;180(10):1345-55. http://dx.doi.org/10.1001/jamainternmed.2020.3539. PMid:32667669.

 

11. Choron RL, Butts CA, Bargoud C, Krumrei NJ, Teichman AL, Schroeder ME, et al. Fever in the ICU: a predictor of mortality in mechanically ventilated COVID-19 patients. J Intensive Care Med. 2021;36(4):484-93. http://dx.doi.org/10.1177/0885066620979622. PMid:33317374.

 

12. Timenetsky KT, Serpa A No, Lazarin AC, Pardini A, Moreira CR, Corrêa TD, et al. The Perme Mobility Index: a new concept to assess mobility level in patients with coronavirus (COVID-19) infection. PLoS One. 2021;16(4):e0250180. http://dx.doi.org/10.1371/journal.pone.0250180. PMid:33882081.

 

13. Ferreira JC, Ho YL, Besen BAMP, Malbouisson LMS, Taniguchi LU, Mendes PV, et al. Protective ventilation and outcomes of critically ill patients with COVID-19: a cohort study. Ann Intensive Care. 2021;11(1):92. PMid:34097145.

 

14. Donato M, Carini FC, Meschini MJ, Saubidet IL, Goldberg A, Sarubio MG, et al. Consensus for the management of analgesia, sedation and delirium in adults with COVID-19-associated acute respiratory distress syndrome. Rev Bras Ter Intensiva. 2021;33(1):48-67. PMid:33886853.

 

15. Payen JF, Chanques G, Futier E, Velly L, Jaber S, Constantin JM. Sedation for critically ill patients with COVID-19: which specificities? One size does not fit all. Anaesth Crit Care Pain Med. 2020;39(3):341-3. http://dx.doi.org/10.1016/j.accpm.2020.04.010. PMid:32360979.

 

16. Michard F, Malbrain ML, Martin GS, Fumeaux T, Lobo S, Gonzalez F, et al. Haemodynamic monitoring and management in COVID-19 intensive care patients: an International survey. Anaesth Crit Care Pain Med. 2020;39(5):563-9. http://dx.doi.org/10.1016/j.accpm.2020.08.001. PMid:32781167.

 

17. Selby LM, Rupp ME, Cawcutt KA. Prevention of central-line associated bloodstream infections: 2021 Update. Infect Dis Clin North Am. 2021;35(4):841-56. http://dx.doi.org/10.1016/j.idc.2021.07.004. PMid:34752222.

 

18. Polimeni A, Leo I, Spaccarotella C, Mongiardo A, Sorrentino S, Sabatino I, et al. Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: a meta-analysis of 35 studies and 6427 patients. Sci Rep. 2021;11(1):10464. http://dx.doi.org/10.1038/s41598-021-89967-x. PMid:34001992.

 

19. Nascimento JH, Costa RL, Simvoulidis LF, Pinho JC, Pereira RS, Porto AD, et al. COVID-19 e injúria miocárdica em UTI brasileira: alta incidência e maior risco de mortalidade intra-hospitalar. Arq Bras Cardiol. 2021;116(2):275-82. http://dx.doi.org/10.36660/abc.20200671. PMid:33470333.

 

20. Metnitz PG, Moreno RP, Fellinger T, Posch M, Zajic P. Evaluation and calibration of SAPS 3 in patients with COVID-19 admitted to intensive care units. Intensive Care Med. 2021;47(8):910-2. http://dx.doi.org/10.1007/s00134-021-06436-9. PMid:34009450.

 

Submission: 02/08/2021

Approved: 19/04/2022

 

AUTHOR CONTRIBUTIONS

Project design: Jesus RM, Toledo LV, Ercole FF

Data collection: Jesus RM, Toledo LV, Jardim JS

Data analysis and interpretation: Jesus RM, Toledo LV, Jardim JS, Pires Júnior JF, Delfim LVV, Coutinho JSL, Souza SM, Ercole FF

Textual writing and/or critical review of the intellectual content: Jesus RM, Toledo LV, Jardim JS, Pires Júnior JF, Delfim LVV, Coutinho JSL, Souza SM, Ercole FF

Final approval of the text to be published: Jesus RM, Toledo LV, Jardim JS, Pires Júnior JF, Delfim LVV, Coutinho JSL, Souza SM, Ercole FF

Responsibility for the text in ensuring the accuracy and completeness of any part of the paper: Jesus RM, Toledo LV, Jardim JS, Pires Júnior JF, Delfim LVV, Coutinho JSL, Souza SM, Ercole FF

 

 

Imagem 1